Long-acting insulin helps people with diabetes maintain normal blood sugar levels throughout the day. Unlike short-acting insulin, it never peaks, keeping an even sugar level in your blood.

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

If you inject the insulin deeper into your muscle, your body will absorb it too quickly, it might not last as long, and the injection ... not to shake the vial. Short-acting insulin that isn ...

Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...

Short-term GHRT was effective and safe without increased risk for cancers among real-world adults with growth hormone deficiency.

Secondary analyses indicated that a reduced-energy diet lowered the need for long-acting insulin therapy at 36 weeks. This improvement did not affect requirements for metformin, short-acting ...

The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year. [caption id ...